Supplementary Figure 6: Adipogenesis-promoting therapy limits leukemic progression in a non-cell autonomous manner.

(a,b) Schematic (a) and FACS/Trypan blue quantification (b) of leukemic blasts disseminated to the spleen from BM progenitors. Human AML-xenografts (Patient #2) were treated with corn oil (vehicle) or 10 mg kg⁻¹ GW1929, as outlined in Fig. 5m. n = 3 (vehicle) and n = 4 (GW1929) independent xenografted mice from 1 experiment. (c) FACS quantification of human AML dissemination in the BM and spleens of xenografted mice (Patient #2). Data points represent individual mice analyzed at various time points post-engraftment, from 1 experiment that was performed independently from drug treatment experiments in panel b. Findings have been replicated in 2 additional experiments. (d) Western blots showing PPARγ protein levels in human AML cells versus healthy human BM-MSCs and in vitro-differentiated human adipocytes. Unprocessed blots can be found in Supplementary Fig. 7. Images are representative of 3 independent Western blots, each with similar results. (e,f) Viability (left) and leukemic progenitor frequency (right) following overnight culture of human AML cells with 0.1% DMSO (0 μM GW1929) or 5–20 μM GW1929. N numbers (and data points) represent independently assayed wells shown separately for 2 experiments (precise n values are indicated in the figure). All data are means ± s.e.m. Statistical significance was assessed by unpaired t-test (b) or one-way ANOVA with Newman–Keuls Multiple Comparison Test (e,f). Source data can be found in Supplementary Table 8.